The Adult Lymphoma Program is part of the Hematologic Oncology Treatment Center. Our specialists are experienced in providing treatment for the many varieties of lymphoid malignancies, including Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), B-cell neoplasms, and T-cell neoplasms.
The Lymphoma Program provides care for the many varieties of lymphoid malignancies, including Non-Hodgkin lymphoma, Hodgkin lymphoma, B-cell neoplasms, and T-cell neoplasms. Your care will involve the best treatments currently available, combined with new therapies based on research in our laboratories and elsewhere in the field of lymphoma treatment.
Our program offers patients access to a multidisciplinary team of lymphoma experts with extensive experience caring for patients with lymphoid malignancies. This experience is particularly important because of the complexity of this type of cancer: There are more than 20 tumor types, each with a unique natural history and each requiring a different approach to treatment.
We provide comprehensive services to patients with lymphoma, including:
The Adult Lymphoma Program treatment team includes physicians and clinicians with extensive experience caring for patients with lymphoid tumors, as well as conducting research of lymphomas.
Arnold Freedman, MD, Clinical DirectorMargaret Shipp, MD, Chief, Division of Hematologic Neoplasia and Program Director, Lymphoma
Philippe Armand, MD, PhDJennifer R. Brown, MD, PhDGeorge Canellos, MDMatthew S. Davids, MDDavid C. Fisher, MDArnold Freedman, MDEric Jacobsen, MDCaron A. Jacobson, MDAnn LaCasce, MDLee M. Nadler, MD
Peter M. Mauch, MDAndrea K. Ng, MD, MPH
Karen Francoeur, RNJeffrey Hellman, PA-CKathleen McDermott, RNKatherine Stephans, NPSusan Twohig, RNBarbara Virchick, NPMichele Walsh, NP
We work closely with our transplant service team when patients require bone marrow/stem cell transplantation.
The goal of the program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.
Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
Lymphoma: 617-632-6246 or 617-632-5138, or use this online form to make an appointment.
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Hematologic Malignancies DivisionDana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Dana-Farber/New Hampshire Oncology-Hematology
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: